Group 1 - Morgan Stanley reports that China Resources Medical (01515) has issued a profit warning for the first half of the year, with net profit attributable to ordinary shareholders expected to decline by 20% to 25% year-on-year [1] - Excluding the 210 million RMB compensation related to the "Yanhua IOT Agreement," the underlying business profit is projected to decrease by 55% to 60%, falling below market consensus and Morgan Stanley's estimates [1] - The company attributes the profit decline to a reduction in average medical insurance reimbursement per visit, indicating increased reimbursement pressure across regions due to DRG/DIP 2.0 [1] Group 2 - Morgan Stanley sets a target price of 3 HKD for China Resources Medical and maintains a "Reduce" rating [1] - The report suggests that the profit decline could negatively impact other hospital operators reliant on public insurance, such as Haijia Medical (06078), Jinxin Fertility (01951), and Aier Eye Hospital (300015.SZ) [1]

摩根士丹利发表研究报告指出，华润医疗发布今年上半年利润警告，普通股股东应占净利润预计按年下 降20%至25%。若剔除与燕化IOT协议相关的2.1亿元补偿，基础业务利润将按年下降55%至60%，低于 市场共识和大摩的预估。大摩予华润医疗目标价3港元，评级"减持"。大摩指出，公司将利润下降归因 于平均医疗保险每次就诊费用减少，显示各地区受DRG/DIP 2.0导致的报销压力加剧。大摩认为这对其 他依赖公共保险的医院营运商，如海吉亚医疗、固生堂、锦欣生殖和爱尔眼科构成负面影响。 ...